See every side of every news story
Get Started
SubscribeLogin
Social Media
Donald Trump
Wrestling
WWE
MLB
Israel-Hamas Conflict
Natural Disasters
Music
Cryptocurrency
Immigration
Tennis
Education
biotuesdays.com image

News from biotuesdays.com

Information about biotuesdays.com

Where is biotuesdays.com located?biotuesdays.com's Website

Media Bias Ratings

Do you diasgree?
Edit bias
Learn more about Media Bias Ratings.

Factuality

Learn more about  Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about  Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top biotuesdays.com News

Political, health leaders among more than 80 new appointees to the Order of Canada
Canadian Politics · Canada

Political, health leaders among more than 80 new appointees to the Order of Canada

46% Left coverage: 22 sources
See the Story
PharmaJet Enters MOU for Needle-Free Vaccine Delivery in Egypt - BioTuesdays
Cairo, Egypt · Cairo

PharmaJet Enters MOU for Needle-Free Vaccine Delivery in Egypt - BioTuesdays

100% Center coverage: 1 sources
Closely held PharmaJet has announced the signing of a Memorandum of Understanding (MOU) with the Egyptian Unified Procurement Authority (UPA) and closely held EVA Pharma. The agreement aims to explore the integration of needle-free delivery of inactivated polio vaccine into Egypt’s routine immunization program. The signing took place in Cairo at the African Health ExCon healthcare conference on June 26. The MOU includes provisions for distributi…See the Story
Future Directions and Unmet Needs in CLL/SLL Treatment

Future Directions and Unmet Needs in CLL/SLL Treatment

Panelist discusses how recent ASCO updates, particularly the SEQUOIA study results, highlight the long-term efficacy of zanubrutinib in high-risk patients and represent the most significant advances in CLL treatment from the meeting.See the Story

MiNK Therapeutics Soars 538% After Cancer Breakthrough - Wall Street Pit

MiNK Therapeutics’ (INKT) stock surged 538% to $49.53 after a patient with treatment-resistant testicular cancer achieved complete remission using agenT-797, lasting over two years without serious side effects. The company’s Phase 2 trial in gastric cancer showed immune activation and extended survival beyond 12 months in patients who failed prior…Cancer · NashvilleSee the Story

Quince appoints Dr. Hassan Abolhassani to SAB - BioTuesdays

Quince Therapeutics (NASDAQ: QNCX) has announced the appointment of leading immunologist, Hassan Abolhassani, MD, PhD, to its scientific advisory board (SAB). Dr. Abolhassani currently serves as assistant professor of clinical immunology and research specialists in the department of medical biochemistry and biophysics at the Karolinska Institutet in Stockholm, Sweden. In a statement, Dr. Mauro Magnani, PhD, chair of Quince’s SAB, commented, “Qui…Maryland · MarylandRead Article

Jeff Ervin joins Allarity as CFO - BioTuesdays

Allarity Therapeutics (NASDAQ: ALLR) has announced the appointment of Jeff Ervin as chief financial officer (CFO), succeeding Alexander Epshinsky, who will remain involved during the transition period. Mr. Ervin brings nearly two decades of executive leadership experience across healthcare, biotech, and other sectors to the role. Most recently, he served as co-chief financial officer at DayDayCook (NYSEM: DDC). He holds an MBA in Finance and Str…Nashville, Tennessee · NashvilleRead Article

Cogent Reports Positive Topline Results From SUMMIT Trial of Bezuclastinib in NonAdvSM - BioTuesdays

Cogent Biosciences (NASDAQ: COGT) has announced positive topline results from the SUMMIT trial of bezuclastinib in patients with non-advanced systemic mastocytosis (NonAdvSM), achieving statistical significance across all primary and secondary endpoints. According to Cogent, based on these results, the company is on track to submit its first new drug application (NDA) to the FDA for bezuclastinib in NonAdvSM by the end of 2025. Additionally, Cog…FDA · DenverSee the Story

Cyclacel highlights publication in Gut showing plogosertib is active in FLC - BioTuesdays

Cyclacel Pharmaceuticals (NASDAQ: CYCC; NASDAQ: CYCCP) has announced the publication of independent research in the peer-reviewed medical journal Gut demonstrating that plogosertib, a PLK1 inhibitor, is active in fibrolamellar hepatocellular carcinoma (FLC)—a rare and hard-to-treat subtype of liver cancer. In the article titled DNAJ-PKAc fusion heightens PLK1 inhibitor sensitivity in fibrolamellar carcinoma, the authors report that the DNAJ-PKAc…Read Article

MedMira Announces Launch of Clinical Trial for Its Multiplo(R) TP/HIV Self-Test in Canada

67% Left coverage: 3 sources
HALIFAX, NS / ACCESS Newswire / July 7, 2025 / MedMira Inc. (MedMira) (TSXV: MIR) and REACH Nexus are excited to announce a clinical trial has officially started earlier than anticipated to evaluate MedMira's Multiplo® TP/HIV rapid test for use…Homelessness · HalifaxSee the Story

BriaCell adds two key clinical sites to Phase 3 study of lead candidate in MBC - BioTuesdays

BriaCell Therapeutics (NASDAQ: BCTX, BCTXW, BCTXZ; TSX: BCT) has announced the addition of two major cancer centers to its ongoing pivotal Phase 3 clinical study of Bria-IMT plus immune checkpoint inhibitor versus physician’s choice in advanced metastatic breast cancer (MBC). The additional sites include the Los Angeles Cancer Network and Smilow Cancer Hospital at New Haven—both of which have 15 satellite locations. According to BriaCell, positi…Maryland · MarylandRead Article

Clearmind doses first patient in trial of MEAI-based treatment for AUD - BioTuesdays

Clearmind Medicine (NASDAQ: CMND; FSE: CWY0) has announced that the first patient has been dosed in its Phase 1/2a clinical trial of its proprietary MEAI-based oral drug candidate, CMND-100, for the treatment of alcohol use disorder (AUD). According to Clearmind, this milestone marks the first time a patient has received the company’s innovative treatment in a clinical setting—a critical step toward the development of a potential new therapy for…Read Article

Breaking News Topics Related to biotuesdays.com

Health icon

Health

Colorado icon

Colorado

Cancer icon

Cancer

Maryland icon

Maryland

Canada icon

Canada

Medical icon

Medical

United States icon

United States

News
For You
SearchBlindspotLocal